RxDoctor Payments Data

Joshua Sussal, MD

Psychiatry · Greenbelt, MDNPI 1922212174

Payments from drug & device makers

$3,363in general payments, 2019–2025

Across 184 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Otsuka America Pharmaceutical, Inc.$486
  • Sunovion Pharmaceuticals Inc.$339
  • Lundbeck LLC$316
  • Takeda Pharmaceuticals U.S.A., Inc.$191
  • Neuronetics, Inc.$150
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,31399%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,363 in reported general payments places this provider in the 85th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$328,139
Medicare patients
207
Services billed
2,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,443
SpravatoEsketamine Hcl23$32,677
VraylarCariprazine Hcl18$25,148
TrintellixVortioxetine Hydrobromide13$18,695
VyvanseLisdexamfetamine Dimesylate16$9,935
Lisdexamfetamine Dimesylate11$5,442
Lurasidone Hcl15$3,889
Venlafaxine Hcl ErVenlafaxine Hcl75$2,706
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$2,369
Divalproex Sodium ErDivalproex Sodium36$2,367
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$2,250
Quetiapine Fumarate68$2,196
Quetiapine Fumarate ErQuetiapine Fumarate18$1,668
Olanzapine86$1,638
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$65$101,44312 claims
Johnson & JohnsonSpravato$110$32,67723 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$191$28,63029 claims
AbbVieVraylar$521$25,14818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →